Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Amicus Therapeutics Inc Market Cap
The Amicus Therapeutics Inc (FOLD) share price is expected to increase by 80.57% over the next year. This is based on calculating the average 12-month share price estimate provided by 13 stock analysts who have covered FOLD. Price targets range from $14 at the low end to $21 at the high end. The current analyst consensus for FOLD is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Amicus Therapeutics Inc has a total of 13 Wall St Analyst ratings. There are 11 buy ratings, 2 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Amicus Therapeutics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of FOLD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Anupam Rama JP Morgan | Overweight | $17 | Maintains | Nov 12, 2024 |
| Debjit Chattopadhyay Guggenheim | Buy | $15 | Maintains | Nov 7, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $21 | Maintains | Nov 7, 2024 |
| Gil Blum Needham | Hold | Reiterates | Nov 7, 2024 | |
| Tazeen Ahmad B of A Securities | Buy | $15 | Maintains | Oct 17, 2024 |
| Jeffrey Hung Morgan Stanley | Overweight | $18 | Maintains | Oct 11, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $20 | Reiterates | Sep 20, 2024 |
| Dennis Ding Jefferies | Buy | $18 | Initiates | Sep 6, 2024 |
| Anupam Rama JP Morgan | Overweight | $16 | Maintains | Aug 16, 2024 |
| Gil Blum Needham | Hold | Reiterates | Aug 9, 2024 | |
Wells Fargo | Overweight | $18 | Initiates | May 30, 2024 |
| Debjit Chattopadhyay Guggenheim | Buy | $13 | Upgrade | May 14, 2024 |
| Jeffrey Hung Morgan Stanley | Overweight | $19 | Maintains | May 10, 2024 |
| Gil Blum Needham | Hold | Reiterates | May 10, 2024 | |
| Tazeen Ahmad B of A Securities | Buy | $13 | Maintains | May 10, 2024 |
| Karl Chalabala UBS | Buy | $19 | Maintains | May 10, 2024 |
| Anupam Rama JP Morgan | Overweight | $19 | Maintains | Mar 18, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $22 | Reiterates | Feb 29, 2024 |
| Jeffrey Hung Morgan Stanley | Overweight | $20 | Upgrade | Dec 19, 2023 |
| Andrew Galler Morgan Stanley | Equal-Weight | $15 | Maintains | Nov 9, 2023 |
When did it IPO
2007
Staff Count
500
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Bradley L. Campbell M.B.A.
Market Cap
$2.94B
In 2023, FOLD generated $399.4M in revenue, which was a increase of 21.30% from the previous year. This can be seen as a signal that FOLD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Amicus Therapeutics (FOLD) reported earnings 30 days ago; investors may look for upcoming developments or announcements that could impact the stock's performance.
Why It Matters - Earnings reports can influence stock performance; investor sentiment may shift based on results. Future guidance and market reactions will affect FOLD's price trajectory.
Thu, 05 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Investors in the Medical - Biomedical and Genetics sector are evaluating Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD) for potential value investment opportunities.
Why It Matters - The comparison between Halozyme Therapeutics and Amicus Therapeutics highlights potential investment opportunities, guiding value investors in making informed decisions based on relative attractiveness.
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A legal case has been initiated by Jeffrey Moats against the National Credit Union Administration Board and Board Member Todd Harper. Further details on the case were not provided.
Why It Matters - The lawsuit against the NCUA Board may impact regulatory policies affecting credit unions, influencing their operational environment and potentially affecting their financial performance.
Tue, 19 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Investors in Medical - Biomedical and Genetics sectors are evaluating Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD) for potential undervalued stock opportunities.
Why It Matters - The comparison between Halozyme Therapeutics and Amicus Therapeutics highlights potential investment opportunities in undervalued biotech stocks, influencing portfolio decisions in the sector.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Saul Ortega and David Rogers have filed a case against the Office of the Comptroller of the Currency. Details on the nature of the lawsuit are not specified.
Why It Matters - The lawsuit against the Office of the Comptroller of the Currency could signal regulatory changes or risks, affecting bank operations and investor confidence in financial institutions.
Thu, 07 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - FOLD reported third-quarter 2024 earnings and sales that exceeded Zacks Consensus estimates and has raised its financial guidance for the year.
Why It Matters - FOLD's earnings and sales surpassing estimates, along with raised guidance, signal strong performance and growth potential, likely boosting investor confidence and stock value.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
